The most important financial indicators for the company Opticlinic Med Srl - Unique Identification Number 28954665:
sales in 2023 was
357.220
euro, registering a net profit of
57.999
euro and having an average number of
5
employees.
Firma isi desfasoara activitatea in domeniul Comert cu amanuntul al altor bunuri noi, in magazine specializate having the NACE code 4778.
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales increased by 44.2%, from 248.488 euro in the year 2022, to 357.220 euro in 2023.
The Net Profit increased by 46.914 euro, from 11.119 euro in 2022, to 57.999 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Opticlinic Med Srl - CUI 28954665
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Fixed Assets
2.178
6.322
7.772
6.072
50.547
81.490
62.989
50.445
109.318
102.845
Current Assets
25.249
25.989
30.729
39.414
75.471
46.197
64.301
53.056
79.528
98.887
Inventories
11.400
16.247
27.634
34.727
23.016
27.878
20.592
31.939
61.589
61.606
Receivables
3.638
3.633
3.096
3.947
19.030
7.302
8.194
1.755
2.967
15.519
Cash
10.212
6.109
-1
740
33.426
11.018
35.515
19.362
14.972
21.762
Shareholders Funds
2.205
3.643
11.674
27.544
63.210
72.847
84.408
71.545
78.617
116.824
Social Capital
45
45
45
44
43
42
41
40
41
40
Debts
25.222
28.668
26.827
17.942
62.807
55.011
43.020
31.956
110.317
85.440
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
4.4821
Main CAEN
"4778 - 4778"
CAEN Financial Year
4778
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
98.887 euro in 2023 which includes Inventories of
61.606 euro, Receivables of
15.519 euro and cash availability of
21.762 euro.
The company's Equity was valued at
116.824 euro, while total Liabilities amounted to
85.440 euro.
Equity increased by 38.445 euro, from 78.617 euro in 2022, to 116.824 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Opticlinic Med Srl